This CRISPR/Cas9-edited polyclonal knockout cell population disrupts the ECH1 gene in the Huh-7 hepatocellular carcinoma cell line, providing a versatile loss-of-function model for studying peroxisomal fatty acid beta-oxidation and lipid metabolism. The product consists of a mixed population of cells with heterogeneous ECH1 gene disruptions, enabling functional studies without clonal selection artifacts. ECH1 enoyl-CoA hydratase 1 catalyzes the hydration of trans-2-enoyl-CoA to 3-hydroxyacyl-CoA, a critical step in the peroxisomal beta-oxidation spiral, and possesses auxiliary delta3,5-delta2,4-dienoyl-CoA isomerase activity for unsaturated fatty acid degradation.
The Huh-7 cell line was established from a liver tumor of a 57-year-old Japanese male in 1982 and is a widely employed epithelial model for hepatocellular carcinoma. Huh-7 cells retain many hepatocyte-like features, including active lipid metabolism and expression of key peroxisomal enzymes, making them particularly suitable for investigating metabolic reprogramming in liver cancer. Their robust growth and responsiveness to pharmacological modulation facilitate high-throughput screening and mechanistic studies linking fatty acid metabolism to oncogenic processes.
ECH1 functions as a core component of the peroxisomal beta-oxidation complex, interacting directly with ACOX1, HSD17B4, and SCP2 to facilitate the sequential catabolism of long-chain and very-long-chain fatty acids. Its expression is transcriptionally activated by PPAR?? and fatty acid-activated PPAR??, situating ECH1 downstream of nutrient-sensing nuclear receptors. The hydration reaction produces 3-hydroxyacyl-CoA, which is further processed to acetyl-CoA, fueling ATP production. Consequently, ECH1 activity directly couples peroxisomal lipid degradation to cellular energy homeostasis and anabolic carbon supply.
In the context of hepatocellular carcinoma, ECH1 knockout in Huh-7 cells abrogates peroxisomal enoyl-CoA hydration, leading to potential accumulation of upstream acyl-CoA esters and reduced flux toward acetyl-CoA and ATP. This metabolic disruption can unmask dependencies on alternative energy pathways and sensitize cells to metabolic stress. The model is thus highly relevant for dissecting how fatty acid oxidation contributes to tumor cell survival, proliferation, and resistance to therapy, as well as for exploring the roles of peroxisomes in non-alcoholic fatty liver disease progression to HCC.
Researchers can employ this polyclonal knockout population to investigate fatty acid metabolism in liver cancer using diverse functional assays, including 14C-palmitate oxidation flux analysis, Oil Red O staining for neutral lipid accumulation, and ATP level quantification. Validation of ECH1 disruption is straightforward via western blotting and RT-qPCR, while downstream effects on global transcription can be assessed by RNA-seq. The cells are also valuable for drug screening campaigns targeting metabolic vulnerabilities in HCC and NAFLD. For further details, please contact Ascent Research.
